(Yicai Global) July 18 -- Andon Health’s shares fell after the Chinese maker of Covid-19 home test kits expressed uncertainty about continued rapid growth following what it expects was a more than 27,000 percent increase in first-half profit from a year earlier.

Andon [SHE: 002432] closed 3.1 percent lower at CNY56.65 (USD8.41), after sinking by as much as 5 percent earlier in the day.

Net profit was likely between CNY15.1 billion and CNY15.5 billion (USD2.2 billion and USD2.3 billion) in the six months ended June 30, the Tianjin-based firm said in a statement on July 15, adding that the spread of Covid-19 in the United States spurred sales of its iHealth kits.

Andon did not provide any future guidance. In view of the unpredictability of the pandemic and changes in market demand and competition, the company said there are uncertainties about its continued rapid growth.

The firm’s stock price soared after the US Food and Drug Administration approved its Covid-19 antigen detection kit early last November. The shares are still up more than 800 percent since then.

Andon also did not release sales figures for the Covid-19 test kits developed by its US unit iHealth Labs.

Editor: Futura Costaglione